首页|期刊导航|中国药房|祛湿活血方通过AMPK/mTOR/ULK1自噬信号通路改善代谢相关脂肪性肝病的作用机制研究

祛湿活血方通过AMPK/mTOR/ULK1自噬信号通路改善代谢相关脂肪性肝病的作用机制研究OA

Mechanism of Qushi huoxue decoction in improving metabolic-associated fatty liver disease through the AMPK/mTOR/ULK1 autophagy signaling pathway

中文摘要英文摘要

目的 基于AMP活化蛋白激酶/哺乳动物雷帕霉素靶蛋白/UNC-51样激酶1(AMPK/mTOR/ULK1)自噬信号通路,探讨祛湿活血方改善代谢相关脂肪性肝病(MAFLD)的作用机制.方法 取雄性C57BL/6J小鼠,分为正常组、模型组和祛湿活血方低、中、高剂量组[4.10、8.20、16.40 mg/(g·d)],每组10只.除正常组外,其余各组小鼠采用高脂饲料喂养12周建立MAFLD模型.造模完成后24 h开始,各组小鼠每日给予相应药液或生理盐水干预,每日1次,持续干预6周.按照试剂盒说明书检测血清总胆固醇(TC)、甘油三酯(TG)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平;采用HE染色、油红O染色观察小鼠肝组织病理变化;采用Western blot、免疫荧光染色法检测小鼠AMPK/mTOR/ULK1自噬信号通路相关蛋白表达及蛋白阳性表达情况.结果 与正常组相比,模型组小鼠血清TC、TG、ALT、AST及LDL-C水平均显著升高,HDL-C水平显著下降(P<0.01);HE染色可见模型组肝细胞出现明显脂肪变性,油红O染色显示小鼠肝组织内有大量脂滴堆积;Western blot和免疫荧光染色结果显示,模型组小鼠肝组织中p-mTOR/mTOR、p62蛋白表达水平以及p-mTOR、p62蛋白的相对荧光强度均显著升高/增强(P<0.01),p-AMPK/AMPK、ULK1、微管相关蛋白1轻链3Ⅱ(LC3Ⅱ)蛋白表达水平以及p-AMPK、LC3蛋白的相对荧光强度均显著降低/减弱(P<0.01).经祛湿活血方干预后,祛湿活血方低、中、高剂量组小鼠上述肝组织病理改变和异常指标均得到显著逆转,大部分指标差异有统计学意义(P<0.05或P<0.01).结论 祛湿活血方可显著改善MAFLD模型小鼠的肝脏病理形态、血脂水平与肝功能,该改善作用可能通过激活AMPK/mTOR/ULK1自噬信号通路实现.

OBJECTIVE To investigate the mechanism of Qushi huoxue decoction in improving metabolic-associated fatty liver disease(MAFLD)based on the AMP-activated protein kinase/mammalian target of rapamycin/UNC-51-like kinase 1(AMPK/mTOR/ULK1)autophagy signaling pathway.METHODS Male C57BL/6J mice were randomly divided into normal group,model group,and low-,medium-,and high-dose Qushi huoxue decoction groups[4.10,8.20,16.40 mg/(g·d)],with 10 mice in each group.Except for the normal group,mice in the other groups were fed a high-fat diet for 12 weeks to establish the MAFLD model.Starting 24 hours after modeling,mice in each group were administered the drug solution or normal saline once daily for 6 consecutive weeks.Serum levels of total cholesterol(TC),triglycerides(TG),alanine transaminase(ALT),aspartate transferase(AST),low-density lipoprotein cholesterol(LDL-C),and high-density lipoprotein cholesterol(HDL-C)were detected according to the kit instructions.Hematoxylin-eosin(HE)staining and oil red O staining were used to observe pathological changes in mouse liver tissue.Western blot and immunofluorescence staining were used to detect the expression and positive protein expression related to the AMPK/mTOR/ULK1 autophagy signaling pathway.RESULTS Compared with the normal group,the serum levels of TC,TG,ALT,AST,and LDL-C in the model group were significantly increased,while the HDL-C level was significantly decreased(P<0.01).HE staining showed obvious steatosis in hepatocytes of the model group,and oil red O staining showed a large amount of lipid droplet accumulation in liver tissue.Western blot and immunofluorescence staining results showed that the expression levels of p-mTOR/mTOR and p62 proteins,as well as the relative fluorescence intensities of p-mTOR and p62 proteins in liver tissue of the model group,were significantly increased/enhanced(P<0.01),while the expression levels of p-AMPK/AMPK,ULK1,and microtubule-associated protein 1 light chain 3 Ⅱ(LC3 Ⅱ)proteins,as well as the relative fluorescence intensities of p-AMPK and LC3 proteins,were significantly decreased/weakened(P<0.01).After intervention with Qushi huoxue decoction,the above pathological changes and abnormal indicators in liver tissue of mice in the low-,medium-,and high-dose groups were significantly reversed,with most indicators showing statistically significant differences(P<0.05 or P<0.01).CONCLUSIONS Qushi huoxue decoction can significantly improve liver pathology,blood lipid levels,and liver function in MAFLD model mice;this improvement may be achieved through the activation of the AMPK/mTOR/ULK1 autophagy signaling pathway.

龚晓倩;谭伟强;魏业煌;王蓉蓉;唐艳芳;刘旭东

广西中医药大学研究生院,南宁 530001广西中医药大学研究生院,南宁 530001广西中医药大学研究生院,南宁 530001广西中医药大学研究生院,南宁 530001广西中医药大学第二附属医院肝病科,南宁 530011广西中医药大学第二附属医院肝病科,南宁 530011

医药卫生

祛湿活血方代谢相关脂肪性肝病AMPK/mTOR/ULK1自噬

Qushi huoxue decoctionmetabolic associated fatty liver diseaseAMPK/mTOR/ULK1autophagy

《中国药房》 2026 (16)

2105-2111,7

国家自然科学基金地区科学基金项目(No.82560866,No.82160837)广西壮族自治区中医药管理局自筹经费科研课题(No.GXZYA20250154)国家中医药管理局全国中医临床优秀人才研修项目(No.国中医药人教发[2022]115号)

10.6039/j.issn.1001-0408.2026.16.05

评论